Epic Sciences
PrivateLast Round
Series G
Apr 14, 2023
Total Funding Raised
$208.2M
Company Overview
Epic Sciences operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series G round in April 2023.
Epic Sciences is a biotechnology company that develops diagnostic tests for the rapid and non-invasive detection of genetic and molecular changes in cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials, Medical Imaging, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epic Sciences Comparables
Compare Epic Sciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| RareCyte | 84% | |
| CellMax Life | 80% | |
| QCDx | 79% |
For institutional investors. Book with your work email.
Epic Sciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series G | Apr 14, 2023 | ||||
| Series F | Jun 1, 2022 | ||||
| Series E | Sep 12, 2018 | ||||
| Series D | Apr 28, 2017 | ||||
| Series C | Jul 30, 2014 | ||||
Grant | Jan 25, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Epic Sciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RusnanoMedInvest | Series C |
| Deerfield Management | Series E, Series F, Series G |
| National Cancer Institute | Grant |
| Roche Venture Fund | Series B, Series C |
| Genomic Health | Series E, Series D |
| Domain Associates | Series E, Series G, Series D, Series C, Series B |
| Altos Capital Partners | Series E, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 14, 2023
$24M round led by Arsenal Capital Partners and Deerfield Management.
- Jun 1, 2022
$43M round led by Arsenal Capital Partners.
For institutional investors. Book with your work email.
Epic Sciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Epic Sciences's valuation, stock price, and market status.
Is Epic Sciences a public or private company?
Epic Sciences is a private company.
What is the current stock price of Epic Sciences?
Epic Sciences is a private company, so its shares have no public market price. Caplight tracks Epic Sciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Epic Sciences worth (valuation)?
Valuation information for Epic Sciences is not publicly available.
Can I buy Epic Sciences stock?
Epic Sciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Epic Sciences's last funding round?
Epic Sciences's most recent funding round was Series G on April 14, 2023.
Who are the main investors in Epic Sciences?
Key investors in Epic Sciences include RusnanoMedInvest, Deerfield Management, Domain Associates, Hermed Capital, Arsenal Capital Partners.
Will Epic Sciences IPO soon?
No public IPO plans have been announced for Epic Sciences.
How can I track Epic Sciences secondary market activity?
Caplight tracks bids, offers, and trades in Epic Sciences's shares on secondary markets.